IO Frontiers World 2019


Masahide Yano

Dr Masahide Yano

Research Scientist, Center for Drug Evaluation & Research, FDA (Provisionally Confirmed)

Dr. Masahide Yano is a research scientist in Center for Drug Evaluation and Research (CDER)at US Food and Drug Administration (FDA). 

Dr. Yano completed his doctoral training at Albert Einstein College of Medicine in New York City, New York where he received his Ph.D. degree on Microbiology and Immunology in 2011.  At Einstein, Dr. Yano worked on immunoglobulin Immune-profiling, and also identified a novel mechanism of antibody-mediated host protection in lethal bacterial infection.  He then underwent on his postdoctoral research fellowship in cellular immunology at FDA, and remain in the agency after the completion of his training.  His current research interests focus on elucidating the immunological mechanisms that cause drug hypersensitivity as well as exploring the application of Next-generation sequencing (NGS)  on T cell receptor repertoires analysis.  Dr. Yano is a world expert in Immuneprofiling in health and disease. 

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy